Antimicrobial management strategies for Gram-positive bacterial resistance in the intensive care unit

Critical Care Medicine

Volumn 29, Issue 4 SUPPL., 2001, Pages

  Schentag, J J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Areas under the inhibitory curve; Gram positive infection; Multiresistant Staphylococcus aureus; PK PD vs. resistance

Indexed keywords

ANTIMIGRAINE AGENT; DALFOPRISTIN PLUS QUINUPRISTIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERIAL INFECTION; DRUG EFFICACY; DRUG TOLERANCE; ENTEROCOCCUS FAECIUM; GRAM POSITIVE BACTERIUM; HUMAN; INTENSIVE CARE UNIT; LOWER RESPIRATORY TRACT INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS AUREUS; TREATMENT FAILURE;

EID: 0035054247     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200104001-00009     Document Type: Review

References (45)

1. Epidemiology of drug resistance: Implications for a post-antimicrobial era
2. The crisis in antibiotic resistance
3. Ciprofloxacin resistance among Pseudomonas aeruginosa and Staphylococcus aureus in the United States
4. Trends in MRSA in United States hospitals
5. Nasal carriage of Staphylococcus aureus as a major risk factor for wound infections after cardiac surgery
6. Nasal colonization with methicillin-resistant Staphylococcus aureus on admission to the surgical intensive care unit increases the risk of infection
7. Genesis of methicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium, and the importance of antibiotic management and infection control
8. Differences in outcome for patients with bacteremia due to VREF or vancomycin susceptible E. faecium
9. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan
10. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection
11. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy
12. Pharmacokinetic and pharmacodynamic activity of ciprofloxacin against strains of S. pneumoniae, S. aureus, and P. aeruginosa for which MICs are similar
13. Comparative antibiotic dose effect relations at several dosing intervals in murine pneumonitis and thigh infection models
14. Pharmacodynamic modeling of the in vitro interaction between cefotaxime and ofloxacin using serum inhibitory tests
15. Mathematical examination of dual individualization principles (II) The rate of bacterial eradication at the same area under the inhibitory curve (AUIC) is more rapid for ciprofloxacin than for cefmenoxime
16. The pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
17. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis
18. Antibiotic dosing issues in lower respiratory tract infection: Population-derived AUIC is predictive of efficacy
19. The importance of pharmacokinetic and pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents
20. Mathematical examination of dual individualization principles (I) relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin
21. Analysis of a new method for assessing activity of combinations of antimicrobials: Area under the bactericidal activity curve
22. AUIC - The universal parameter within the constraint of a reasonable dosing interval
23. Area under the inhibitory curve and a pneumonia scoring system for outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus
24. Pharmacodynamic interactions of antibiotics alone and in combination
25. Understanding and managing microbial resistance in institutional settings
26. Reasons for the emergence of antibiotic resistance
27. Vancomycin serum protein binding determination by ultrafiltration
28. The influence of serum albumin and alpha 1-acid glycoprotein on vancomycin protein binding in patients with burn injuries
29. Vancomycin protein binding in patients with infections caused by Staphylococcus aureus
30. Emergence of vancomycin resistance in coagulase-negative staphylococci
31. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis to Staphylococcus aureus
32. Vancomycin resistant Staphylococcus aureus: Perspectives on measures needed for control
33. A comparison of clinical virulence of nosocomially acquired MRSA and MSSA in a university hospital
34. Mortality associated with nosocomial bacteremia due to MRSA
35. Economic justification of antimicrobial management programs: Implications of antimicrobial resistance
36. Selecting cost-effective antimicrobial prophylaxis in surgery: Are we getting what we pay for?
37. Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance?
38. Methicillin resistant Staphylococcus aureus: A consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management
39. Methicillin resistant Staphylococcus aureus in hospitals and long term care facilities: Microbiology, epidemiology, and preventive measures
40. Changing the infection control paradigm from offline to real-time: The experience at Millard Fillmore Health System
41. Antibiotic cost savings from formulary restrictions and physician monitoring in a medical affiliated hospital
42. Ceftazidime in the elderly: Economic implications
43. Use of benchmarking techniques to analyze the strategies hospitals use to control antibiotic expenditures
44. Influence of fluoroquinolone purchasing patterns on antimicrobial expenditures and Pseudomonas aeruginosa susceptibility
45. Formulary management vs disease management